Analysts| Firm | Analyst | | Burrill Institutional Research | Reni Benjamin, Ph.D. | | Canaccord Genuity | Ritu Baral | | Cowen and Company | Edward Nash | | Deutsche Bank | Robyn Karnauskas | | Emerging Growth Equities, Ltd. | Debjit Chattopadhyay, Ph.D., MBA | | Janney Capital Markets | Kimberly Lee, D.O. | | JMP Securities | Liisa Bayko | | Lazard Capital Markets | William Tanner, Ph.D | | Leerink Swann | Joseph P. Schwartz | | Needham & Company | Chad Messer | | Piper Jaffray & Co. | Edward A. Tenthoff | | Robert W. Baird & Co. | Brian Skorney, CFA | | WBB Securities, LLC | Stephen G. Brozak | | Wedbush Securities | Christopher N. Marai, Ph.D. | | William Blair | Tim Lugo |
|
 |
| Sarepta Therapeutics Inc is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Sarepta Therapeutics Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sarepta Therapeutics Inc or its management. Sarepta Therapeutics Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
